Paliperidone
Inherited Lipid Metabolism Disorder
Explore 18 assets in Inherited Lipid Metabolism Disorder →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06060886CT.gov Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Inherited Lipid Metabolism Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Paliperidone (this asset) | Consorcio Centro de Investigación Biomédica en Red (CIBER) | Approved | BB · 65 |
| Atorvastatin | Johns Hopkins University | P4 | A |
| Rosuvastatin | Korea University Anam Hospital | P4 | A |
| Metformin | RenJi Hospital | P4 | BBB |
| Simvastatin | Eli Lilly and Company | P4 | BBB |
| Ezetimibe | Samsung Medical Center | P4 | BBB |
| Fenofibrate | Lewai Sharki Abdulaziz, MSc PhD | P4 | BBB |
| Umbellatine | China National Center for Cardiovascular Diseases | P4 | BBB |
| Retrovir | Kirby Institute | P4 | BB |
+42 more in the Inherited Lipid Metabolism Disorder cohort
Other indications for Paliperidone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizoaffective Disorder | — | P4 | BBB · 78 |
| Psychotic Disorder | — | P4 | BBB · 76 |
| Schizophrenia | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Paliperidone in Inherited Lipid Metabolism Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/paliperidone-inherited-lipid-metabolism-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →